Shopping Cart
Remove All
Your shopping cart is currently empty
Sudubrilimab (HS636), an Ig G1-kappa monoclonal antibody targeting PDL1, is engineered with a TGF-β1 receptor II ectodomain (TGFBR2-ECD) fused to its C-terminus. This design enables Sudubrilimab to simultaneously inhibit the PD-1/PD-L1 pathway and TGF-β bioactivity within the immunosuppressive tumor microenvironment [1].
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | Inquiry | Inquiry | Inquiry |
| Description | Sudubrilimab (HS636), an Ig G1-kappa monoclonal antibody targeting PDL1, is engineered with a TGF-β1 receptor II ectodomain (TGFBR2-ECD) fused to its C-terminus. This design enables Sudubrilimab to simultaneously inhibit the PD-1/PD-L1 pathway and TGF-β bioactivity within the immunosuppressive tumor microenvironment [1]. |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | PD-L1 |
| Isotype | IgG1 |
| Storage | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.